Monovalent Antibody Design and Mechanism of Action of Onartuzumab, a MET Antagonist With Anti-Tumor Activity as a Therapeutic Agent

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.1302725110
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-C-Met Antibody Onartuzumab (MetMAb) in the Second- And Third-Line Non-Small Cell Lung Cancer

AAPS Journal
Pharmaceutical Science
2016English

Mechanism of Action of a New Anti-Cd38 Antibody: Enhancing Myeloma Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Assessment of Silibinin as a Potential Antifungal Agent and Investigation of Its Mechanism of Action

IUBMB Life
BiochemistryGeneticsClinical BiochemistryCell BiologyMolecular Biology
2017English

Hypnotism as a Therapeutic Agent.

The Lancet
Medicine
1890English

Anti-Antibody Activity of a Monoclonal Macroglobulin

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1971English

Synergistic Anti-Tumor Therapy by a Comb-Like Multifunctional Antibody Nanoarray With Exceptionally Potent Activity

Scientific Reports
Multidisciplinary
2015English

Characterization of a Membrane-Active Anti-Tumor Agent, UA8967

Investigational New Drugs
OncologyPharmacology
2012English

Mechanism Study of Isoflavones as an Anti-Retinoblastoma Progression Agent

Oncotarget
Oncology
2017English

89Zr-Onartuzumab PET Imaging of C-Met Receptor Dynamics

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy